Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET
Company Participants
Marek Ciszewski – Investor Relations
Denny Lanfear – Chief Executive Officer
Rosh Dias – Chief Medical Officer
Paul Reider – Chief Commercial Officer
McDavid Stilwell – Chief Financial Officer
Conference Call Participants
Ken Cacciatore – Cowen and Company
Douglas Tsao – H.C. Wainwright & Company
Jason Gerberry – Bank of America
Ash Verma – UBS
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Q2 2022 Coherus BioSciences, Inc. Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Marek. Please go ahead.
Marek Ciszewski
Thank you, Mandeep. Good afternoon, everyone, and thank you for joining us. We issued a press release earlier announcing our financial results for the second quarter of 2022. This release can be found on the Coherus BioSciences website and is also attached to our Form 8-K.
Today’s call includes forward-looking statements regarding Coherus’ current expectations about future events. These statements include, but are not limited to, our ability to launch multiple new products, our ability to generate sufficient sales to achieve revenue growth and profitability, our SG&A and R&D expense guidance, our projected market share, our 2026 top line projections, our projections about market opportunities and our ability to advance our product candidates and successfully launch our products according to our projected time line.
All these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from results, performance or achievements implied by the forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties that are discussed in our press release that we issued today as well as the documents that we file with the SEC, including those in our quarterly report on Form 10-Q for the second quarter that we filed today. Forward-looking statements provided on the call today are made as of this date, and we undertake no duty to update or revise any forward-looking statements.
With me on today’s call are Denny Lanfear, CEO of Coherus; Paul Reider, Chief Commercial Officer; Dr. Rosh Dias, Chief Medical Officer; and McDavid Stilwell, Chief Financial Officer. Our Chief Development Officer, Dr. Theresa LaVallee, is traveling on vacation and is unable to join us.
I will now turn the call over to Denny.